Evotec
Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.
41 past transactions
Aptadir Therapeutics
Pre Seed Round in 2024
Aptadir Therapeutics is a biotechnology company focused on developing novel treatments for diseases associated with abnormal DNA methylation. The company's approach involves using RNA therapeutics to inhibit the function of DNMT1, an enzyme responsible for adding methyl groups to DNA. Specifically, Aptadir is working on a treatment for Myelodysplastic Neoplasms, a group of conditions that affect the blood and bone marrow.
Aeovian Pharmaceuticals
Series A in 2024
Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area, specializing in the development and commercialization of innovative therapeutics targeting age-related and rare diseases. Founded in 2012, the company focuses on creating compounds that inhibit the mTORC1 and mTORC2 pathways, which are critical in addressing the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these molecular pathways, Aeovian Pharmaceuticals aims to provide effective treatment options for patients and healthcare providers. The company was previously known as Delos Pharmaceuticals, reflecting its commitment to advancing therapeutic solutions in the biopharmaceutical sector.
Tubulis
Series B in 2024
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Carrick Therapeutics
Series C in 2022
Carrick Therapeutics, Ltd. is a Dublin-based company founded in 2015 that specializes in the development of innovative cancer therapeutics. The company focuses on targeting molecular pathways associated with aggressive and resistant forms of cancer. By employing advanced mechanisms, Carrick Therapeutics aims to transform cancer treatment and improve patient outcomes. Their approach facilitates the early detection of predictive biomarkers, allowing for timely initiation of personalized treatments.
Cajal Neuroscience
Series A in 2022
Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. It employs a combination of human genetics, functional genomics, and advanced microscopy techniques to identify novel targets and therapeutics. The company utilizes viral tools and platforms for screening targets that influence the progression of neurodegenerative conditions, alongside functional genetic screening and multi-omics methods. By integrating these state-of-the-art approaches, Cajal Neuroscience aims to advance precision medicine, ultimately enabling healthcare professionals to improve treatment outcomes for patients suffering from neurodegenerative disorders.
Central Glass Germany
Acquisition in 2022
Central Glass Germany develops and manufactures chemical base materials, cosmetic ingredients, and pharmaceutical intermediates. It serves the pharmaceutical, cosmetics, and food industries and other sectors, producing fine chemicals and offering synthesis research and process development services, regulatory support, stability studies, and clinical development.
Rigenerand Srl
Acquisition in 2022
Rigenerand Srl is a biomedical company based in Medolla, Italy, established in 2009 by Prof. Massimo Dominici and Prof. Pierfranco Conte. It specializes in the development and production of devices that support the culture of stem cells for both pre-clinical and clinical applications. The company focuses on enhancing the ex-vivo phase of stem cell expansion by utilizing innovative biocompatible materials to achieve high cell yields. Rigenerand's product pipeline includes various reabsorbable biomaterials for tissue engineering, improved transport systems for direct stem cell delivery to patients, and 3D cell culture systems designed for drug discovery and delivery. The company's technology emerges from a collaboration between a biomedical firm and researchers from the University of Modena and Reggio Emilia.
Tubulis
Series B in 2022
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Centauri Therapeutics
Series A in 2022
Centauri Therapeutics is a biotechnology company that develops novel immunotherapeutics employing a dual‑mechanism platform. Its molecules combine a cell‑surface antigen‑binding moiety with a glycan effector domain that harnesses the body’s pre‑existing polyclonal antibodies. This design amplifies complement fixation, antibody‑dependent cellular cytotoxicity, and phagocytosis, enabling targeted cell death. The company’s pre‑clinical studies demonstrate potent enhancement of complement fixation and opsonophagocytosis for both antibacterial and oncology agents, and in vivo proof of concept in multiple infection models. Centauri also utilizes alphamer technology, chemically synthesizing molecules that redirect endogenous antibodies to specific pathogens, providing a new approach to treating infectious diseases. The company focuses on life‑threatening conditions, aiming to bring innovative therapies to patients.
IMIDomics
Corporate Round in 2022
IMIDomics is a specialized company focused on addressing Immune-Mediated Inflammatory Diseases (IMIDs). It operates by leveraging the world's largest biobank dedicated to IMIDs, alongside its extensive clinical expertise and advanced genomic analysis capabilities. The company develops an analytical platform that provides healthcare professionals with accessible insights from vast amounts of molecular and clinical data, facilitating optimized treatment strategies for patients with IMIDs. With locations at Vall d'Hebron Hospital in Barcelona, Spain, and the HudsonAlpha Institute in Huntsville, Alabama, IMIDomics aims to advance the understanding and management of these complex diseases through innovative biomarker discovery and application.
Topas Therapeutics
Series B in 2021
Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.
OxVax
Seed Round in 2021
OxVax Ltd. is a biotechnology company that originated as a spin-out from the University of Oxford. It specializes in the development of an innovative dendritic cell vaccine platform aimed at treating solid tumor cancers. The company's technology utilizes induced pluripotent stem cells (iPSC) to generate CD141+ dendritic cells, a proprietary subset known for their unique properties that enhance their potential as candidates for cancer immunotherapy. By focusing on these specialized cells, OxVax seeks to provide effective treatments for patients battling difficult-to-treat cancers.
Exscientia
Series C in 2021
Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.
Argobio Studio
Funding Round in 2021
Argobio Studio is a start-up studio dedicated to developing innovative therapeutic solutions and launching biotech firms. The studio sources advanced early-stage projects from top European academic research institutions, focusing on areas such as rare diseases, neurological disorders, oncology, and immunology. Argobio aims to cultivate these projects to create promising platform technologies for therapeutic products. By providing financial support and operational expertise, the studio facilitates the growth of early-stage biotechnology initiatives, enabling startups to enhance their medicinal and drug research processes.
Blacksmith Medicines
Seed Round in 2021
Blacksmith Medicines is focused on developing innovative therapies that target metal-dependent enzymes, known as metalloenzymes, which play a crucial role in human physiology. With over 30% of known enzymes classified as metalloenzymes, they encompass all major enzyme classes, including oxidoreductases, transferases, and hydrolases. Blacksmith Medicines utilizes a specialized platform that combines a curated library of metal-binding pharmacophores with advanced computational modeling techniques. This approach allows for the rapid and systematic design of small molecule inhibitors that specifically interact with key metal ions within the enzyme's active site. The company's efforts are particularly directed towards creating medicines for immuno-oncology and inflammatory diseases, offering the potential for more effective and selective therapeutic options.
Autobahn Labs
Seed Round in 2020
Autobahn Labs is a biotechnology company founded in 2018 and based in Palo Alto, California. It focuses on accelerating the development of novel therapeutics by collaborating with early-stage academic research projects. Through a partnership with Evotec, Autobahn Labs leverages expertise in drug discovery and development to identify promising research initiatives. The company provides a dedicated team with substantial scientific and operational knowledge, coupled with industrialized drug discovery capabilities and funding. This approach enables research institutions to advance their projects more rapidly, aiming to transform innovative scientific discoveries into preclinical drug candidates that can lead to new therapeutic options for patients.
Exscientia
Series C in 2020
Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.
Leon Nanodrugs
Series B in 2020
Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.
Immunitas Therapeutics
Series A in 2019
Immunitas Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing targeted therapeutics for patients with complex cancers. Founded in 2019, the company utilizes a single-cell sequencing platform to analyze the biology of immune cells within human tumors. This innovative approach allows Immunitas to identify novel drug targets and develop key biomarkers that guide patient selection for their therapies. By emphasizing research rooted in human biology, Immunitas aims to bridge the gap between laboratory discoveries and clinical applications. The company is advancing multiple programs toward early human studies, leveraging its expertise in antibody discovery and engineering to create effective treatments that modulate identified targets.
Aeovian Pharmaceuticals
Series A in 2019
Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area, specializing in the development and commercialization of innovative therapeutics targeting age-related and rare diseases. Founded in 2012, the company focuses on creating compounds that inhibit the mTORC1 and mTORC2 pathways, which are critical in addressing the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these molecular pathways, Aeovian Pharmaceuticals aims to provide effective treatment options for patients and healthcare providers. The company was previously known as Delos Pharmaceuticals, reflecting its commitment to advancing therapeutic solutions in the biopharmaceutical sector.
Breakpoint Therapeutics
Venture Round in 2019
Breakpoint Therapeutics GmbH, based in Hamburg, Germany, is dedicated to the discovery and development of innovative anti-cancer drugs. The company focuses on targeting the DNA damage response (DDR) in cancer cells, aiming to create first-in-class oncology drugs that disrupt DNA repair mechanisms and replication stress tolerance pathways. By developing therapeutics that complement existing treatments, such as PARP inhibitors, Breakpoint Therapeutics seeks to address the challenges posed by therapy-resistant cancers, ultimately striving to improve patient outcomes in oncology.
Just - Evotec Biologics
Acquisition in 2019
Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at expanding global access to these treatments. The company leverages its expertise in antibody discovery, molecular design, and manufacturing processes to create innovative solutions that accelerate the development of biotherapeutics while significantly lowering manufacturing costs. Utilizing machine learning-driven technologies, Just Evotec Biologics provides clients with integrated designs that streamline the entire process from development to production, ensuring efficient and effective delivery of biologic therapies.
Celmatix
Venture Round in 2019
Celmatix Inc. is a personalized medicine company dedicated to advancing women's health, particularly in the areas of reproductive health and fertility. Founded in 2009 and based in New York, the company has developed innovative solutions such as POLARIS, a web-based analytics platform that assesses a woman's likelihood of success with various fertility treatments based on her clinical metrics. Additionally, Celmatix offers NOVA, a patient portal designed to enhance the patient experience within clinics. By leveraging predictive analytics and genomics, the company enables women to make informed decisions regarding their fertility while equipping healthcare providers with data-driven tools for improved patient care. Celmatix has also established a strategic alliance with Evotec to further its research and development endeavors.
Exscientia
Series B in 2019
Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.
Exscientia
Series A in 2017
Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.
Aptuit
Acquisition in 2017
Aptuit, LLC offers a comprehensive range of integrated drug development services tailored for the pharmaceutical industry, spanning from early discovery to mid-phase development. The company's expertise encompasses drug design, active pharmaceutical ingredient (API) development and manufacturing, solid-state chemistry, and regulatory programs that support preclinical and Investigational New Drug (IND) submissions. With facilities located in the UK, Italy, and Switzerland, Aptuit provides its biopharma partners with synergistic scientific capabilities across drug discovery, preclinical testing, and both drug substance and product manufacturing. This integrated approach enables efficient solutions and accelerates the translation of drugs into clinical trials. Aptuit is also backed by Welsh, Carson, Anderson & Stowe, a prominent private equity investor.
Forge Therapeutics
Series A in 2017
Forge Therapeutics, Inc. is a biotechnology company focused on discovering and developing innovative therapeutics through a unique chemistry platform that targets metalloproteins. The company specializes in creating novel antibiotics aimed at combating multi-drug resistant bacteria. By employing a proprietary approach that combines bioinorganic and medicinal chemistry, Forge develops selective small molecule inhibitors that target metalloenzymes, particularly in gram-negative bacteria. This strategy enables healthcare professionals to effectively access various biochemical processes and biological catalysis essential for treating challenging diseases.
Eternygen
Series A in 2017
Eternygen GmbH is a biotechnology company based in Berlin, Germany, with an additional office in the United Kingdom, founded in June 2012. The company specializes in the research and development of innovative therapies for dietary-related metabolic diseases, which have been increasingly prevalent in recent decades. Eternygen focuses on developing NaCT inhibitors, targeting the sodium-coupled citrate transporter, a crucial regulator of lipid metabolism implicated in conditions such as fatty liver, diabetes, and obesity. By employing a network of esteemed scientists and contract research organizations, Eternygen aims to create safe and effective treatments that address the underlying metabolic failures associated with these widespread diseases.
Cyprotex
Acquisition in 2016
Cyprotex PLC is a provider of preclinical ADME Tox services, focusing on absorption, distribution, metabolism, excretion, and toxicity/pharmacokinetic information for pharmaceuticals and other chemicals. Founded in 1999 and headquartered in Macclesfield, United Kingdom, the company delivers a wide range of in vitro and in silico services. Its offerings include metabolism studies, permeability assessments, toxicology evaluations, and physicochemical profiling, alongside custom assay development. Cyprotex uses advanced modelling approaches to predict human pharmacokinetics and toxicity from chemical structures, catering to pharmaceutical, biotechnology, cosmetics, agrochemical, and academia sectors. The company plays a critical role in enhancing drug safety and efficacy predictions, ensuring compliance with regulatory standards for its diverse clientele in Europe, North America, and internationally.
Carrick Therapeutics
Series A in 2016
Carrick Therapeutics, Ltd. is a Dublin-based company founded in 2015 that specializes in the development of innovative cancer therapeutics. The company focuses on targeting molecular pathways associated with aggressive and resistant forms of cancer. By employing advanced mechanisms, Carrick Therapeutics aims to transform cancer treatment and improve patient outcomes. Their approach facilitates the early detection of predictive biomarkers, allowing for timely initiation of personalized treatments.
Sanofi Oncology
Post in 2014
Sanofi Oncology, a division of global healthcare company Sanofi, focuses on developing and delivering innovative treatments for various types of cancer. With a rich heritage in oncology, Sanofi Oncology leverages its extensive knowledge base to research and treat cancer from multiple angles, addressing diverse patient needs and disease stages. The company's portfolio includes therapies for rare diseases, immunology, and cardiovascular conditions, among others. Sanofi's commitment to patients drives its strategy to create long-term value through innovative treatments, from research and development to manufacturing and marketing.
Euprotec
Acquisition in 2014
Euprotec is a collaborative preclinical Contract Research Organisation that specializes in providing contract research services to companies involved in the discovery and development of new drugs. The company focuses on addressing infections, respiratory diseases, and allergies, offering expertise and support throughout the research process. By partnering with pharmaceutical and biotechnology firms, Euprotec plays a crucial role in advancing the development of innovative therapeutic solutions.
Bionamics
Acquisition in 2014
Bionamics GmbH is an asset management company based in Hamburg, Germany, specializing in project management services for pharmaceutical companies. The firm focuses on acquiring and licensing life science assets that are in the pre-clinical phase, thereby facilitating the transition from innovative research projects to viable development programs in the industry. By bridging the gap between research and the pharmaceutical sector's needs, Bionamics plays a critical role in advancing pre-clinical and clinical development initiatives.
Cell Culture Service GmbH
Acquisition in 2013
Cell Culture Service GmbH (CCS), a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and Pharmaceutical companies. CCS is one of the leading suppliers of custom cells and cell-based reagents such as recombinant assay cell lines, assay-ready Frozen Instant Cells, qualified membranes, and proteins for high throughput screening with more than ten years experience in bulk cell production.
Compound Focus
Acquisition in 2011
Compound Focus, Inc. offers molecule compound management services for liquid and solid compounds.
KINAXO Biotechnologies
Acquisition in 2011
KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. They are a service company specializing in chemical proteomics methods to support the successful development of small molecule drugs. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, they continuously expand and improve their technology platform in collaboration with the leading Max Planck laboratories of Axel Ullrich, Henrik Daub and Matthias Mann. KINAXO offers its clients extensive experience in cellular target profiling and other chemical proteomics applications.
Develogen AG
Acquisition in 2010
Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.
Evotec (India) Private
Acquisition in 2009
Evotec (India) Private Limited provides drug discovery and development services for pharmaceutical, biotech, and fine chemical industries.
Renovis
Acquisition in 2007
Renovis, Inc. is a biopharmaceutical company focused on developing innovative drugs for neurological diseases and disorders. The company is actively engaged in creating treatments for acute ischemic stroke, neuropathic pain, and acute post-operative pain. Utilizing advanced techniques in molecular biology, medicinal chemistry, and pharmacology, Renovis identifies and selects small molecule drug candidates that adhere to rigorous development standards. Through a combination of in vitro and in vivo studies, drug metabolism and pharmacokinetics assessments, and toxicological evaluations, Renovis aims to deliver effective therapeutic solutions to address significant unmet medical needs in neurology.
Evotec Neurosciences
Acquisition in 2005
Evotec Neurosciences GmbH is a biotechnology company focused on the discovery and development of small molecule drugs aimed at treating Alzheimer's disease and other neurological disorders. The company utilizes innovative approaches to develop therapeutics that address significant unmet medical needs in the field of neuroscience. By leveraging advanced scientific techniques and expertise, Evotec Neurosciences aims to contribute to the advancement of treatments for complex neurological conditions.
Oxford Asymmetry International
Acquisition in 2000
Oxford Asymmetry International serves as an outsourcing partner for pharmaceutical companies, specializing in chemical discovery and development services. The company caters to the needs of the pharmaceutical, biotechnology, and agrochemical sectors by developing chiral chemicals and advanced organic compounds. Through its various divisions, it provides essential compounds for screening, utilizing expertise in organic chemistry, polymer technology, analytical methods, and automation. This comprehensive approach enables clients to enhance and streamline their chemistry processes efficiently and effectively.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.